Financial Information

2022 covers September 23–December 31. FY 2023–2025 covers January–December. The 2026 interim period is not a full year and has not been annualized. Pending means not established on a reconciled, comparable basis; it does not mean zero.

1. The May 28, 2026 annual P&L reports $117,068.22 sales/services and a $45,301.32 net loss. A separate consolidated draft reports $353,969 revenue and $547,302 net loss. Entity scope, consolidation, adjustments and grant classification remain unreconciled; the historical figures above follow the underlying annual P&L, not the investor graphic.
2. 2026 YTD covers January 1–October 23, 2026 and is an unaudited preliminary accrual conversion prepared October 24, 2026, prior to CPA review. Preliminary sales and service revenue of $176,619.18 includes earned device sales to GetHairMD and SportsIQ and provisional eStore revenue (see the revenue reconciliation below); it is not a completed GAAP revenue reconciliation. Other product COGS, inventory, expense cutoffs and remaining accruals are unresolved, so gross profit, total operating expenses and net income are not yet determinable.
3. Historical expense captions follow the source statements; the 2023 and 2024 totals include interest expense. They are not uniformly classified operating expense totals.
4. 2025 other income includes a $250,000 XPRIZE research grant and $3,782.12 miscellaneous income. Grant income is shown separately from product/service sales.
5. 2022 launch-period basis: Figures reflect Lionheart Health, Inc.’s direct bank-account activity from account opening on September 23 through December 31, 2022. They exclude allocated support from Leonhardt Ventures LLC and Cal-X Stars Business Accelerator, Inc.
6. Factory cost of $640 per Lionheart 240 Stimulus device, FOB Amparo, Brazil, for 20 delivered units (detail below). It excludes freight, insurance, duties and customs handling, which will be allocated to units sold when documented.
7. Non-cash estimate of executive compensation earned January 1–October 23, 2026 at prior management accrual rates. It may be reduced to $0 if conditioned restricted stock is accepted. Payroll taxes, interest and stock compensation remain pending.

The 2026 sales forecast is management’s estimate and is not YTD revenue. Loans, equity proceeds and founder funding are not sales.

Basis: 37,599,114 existing common shares + 18,407,910.67 listed options/warrants − 580,300 Dave Boyd options/warrants. Holdings are shown separately by registered holder.

* Subject to increase change with convertible debt note or earned pay conversion.

** Subject to reduction change.